134 related articles for article (PubMed ID: 16282905)
21. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
22. Lymphocyte data in Epstein-Barr-virus induced post-transplant lymphoproliferative disorder treated by rituximab.
Entz-Werle N; Cojean N; Barats A; Eyer D; Munzer M; Uring-Lambert B; Falkenrodt A; Babin A; Lutz P
Pediatr Transplant; 2003 Aug; 7(4):277-81. PubMed ID: 12890005
[TBL] [Abstract][Full Text] [Related]
23. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement.
Hänel M; Fiedler F; Thorns C
Onkologie; 2001 Oct; 24(5):491-4. PubMed ID: 11694778
[TBL] [Abstract][Full Text] [Related]
24. Posttransplant Lymphoproliferative Disorder of the Thorax: CT and FDG-PET Features in a Single Tertiary Referral Center.
Yoon GY; Kim MY; Huh JR; Jo KW; Shim TS
Medicine (Baltimore); 2015 Aug; 94(31):e1274. PubMed ID: 26252295
[TBL] [Abstract][Full Text] [Related]
25. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield.
Montes de Jesus FM; Kwee TC; Kahle XU; Nijland M; van Meerten T; Huls G; Dierckx RAJO; Rosati S; Diepstra A; van der Bij W; Verschuuren EAM; Glaudemans AWJM; Noordzij W
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):529-536. PubMed ID: 31444510
[TBL] [Abstract][Full Text] [Related]
27. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
Jain AB; Marcos A; Pokharna R; Shapiro R; Fontes PA; Marsh W; Mohanka R; Fung JJ
Transplantation; 2005 Dec; 80(12):1692-8. PubMed ID: 16378063
[TBL] [Abstract][Full Text] [Related]
28. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
29. Adalimumab-Induced Epstein-Barr Virus-Related Lymphoproliferative Disorder on FDG PET/CT.
Ward J; Noy A; Ulaner G; Riedl C
Clin Nucl Med; 2018 May; 43(5):344-345. PubMed ID: 29538028
[TBL] [Abstract][Full Text] [Related]
30. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.
Faye A; Quartier P; Reguerre Y; Lutz P; Carret AS; Dehée A; Rohrlich P; Peuchmaur M; Matthieu-Boué A; Fischer A; Vilmer E
Br J Haematol; 2001 Oct; 115(1):112-8. PubMed ID: 11722420
[TBL] [Abstract][Full Text] [Related]
31. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease.
Pham PT; Wilkinson AH; Gritsch HA; Pham PC; Miller JM; Lassman CR; Danovitch GM
Transplant Proc; 2002 Jun; 34(4):1178-81. PubMed ID: 12072308
[No Abstract] [Full Text] [Related]
32. Successful treatment of intraocular post-transplant lymphoproliferative disorder with intravenous rituximab.
Iu LP; Yeung JC; Loong F; Chiang AK
Pediatr Blood Cancer; 2015 Jan; 62(1):169-72. PubMed ID: 25174958
[TBL] [Abstract][Full Text] [Related]
33. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
34. Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients.
Marom EM; McAdams HP; Butnor KJ; Coleman RE
J Thorac Imaging; 2004 Apr; 19(2):74-8. PubMed ID: 15071322
[TBL] [Abstract][Full Text] [Related]
35. Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder.
Hirokawa M; Kawabata Y; Fujishima N; Yoshioka T; Sawada K
Int J Hematol; 2007 Oct; 86(3):291-2. PubMed ID: 17989001
[No Abstract] [Full Text] [Related]
36. Isolated pleural PTLD after cardiac transplantation.
Lamba M; Jabi M; Padmore R; Sengar DP; Veinot JP
Cardiovasc Pathol; 2002; 11(6):346-50. PubMed ID: 12459436
[TBL] [Abstract][Full Text] [Related]
37. Posttransplant lymphoproliferative disorder of the lung in a renal transplant recipient treated successfully with surgery.
Foroncewicz B; Mucha K; Usiekniewicz J; Chmura A; Kryst P; Sołdacki D; Paczek L
Transplant Proc; 2006; 38(1):173-6. PubMed ID: 16504695
[TBL] [Abstract][Full Text] [Related]
38. Recurrent posttransplant lymphoproliferative disorder involving the larynx and trachea: case report and review of the literature.
Banks CA; Meier JD; Stallworth CR; White DR
Ann Otol Rhinol Laryngol; 2012 May; 121(5):291-5. PubMed ID: 22724273
[TBL] [Abstract][Full Text] [Related]
39. 18F-FDG PET for Detection of Primary Tracheobronchial T-/Natural Killer-Cell-Derived Posttransplant Lymphoproliferative Disorder After Lung Transplantation.
Derlin T; Braubach P; Kreipe HH; Hueper K
Clin Nucl Med; 2017 Dec; 42(12):988-989. PubMed ID: 29076909
[TBL] [Abstract][Full Text] [Related]
40. Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease.
Bitzan M; Ouahed JD; Carpineta L; Bernard C; Bell LE
Pediatr Nephrol; 2010 Jun; 25(6):1163-7. PubMed ID: 20140460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
